使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Chris Potochar - Vice President of Treasury and Investor Relation
Chris Potochar - Vice President of Treasury and Investor Relation
Good morning, everyone. Thank you for joining us for our third quarter 2026 earnings call. Mark Bertolini, Oscar Health's Chief Executive Officer; and Scott Blackley, Oscar Health's Chief Financial Officer, will host this morning's call. This call can also be accessed through our Investor Relations website at ir.oscarhealth.com.
各位早安。感謝各位參加我們 2026 年第三季財報電話會議。Oscar Health 執行長 Mark Bertolini 與 Oscar Health 財務長 Scott Blackley 將主持今天上午的會議。本次電話會議亦可透過我們的投資人關係網站 ir.oscarhealth.com 收聽。
Full details of our results and additional management commentary are available in our earnings release, which can be found on our Investor Relations website at ir.oscarhealth.com. Any remarks that Oscar makes about the future constitute forward-looking statements within the meaning of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
我們的業績完整細節與管理層補充評論已載於財報新聞稿,可於我們的投資人關係網站 ir.oscarhealth.com 查閱。Oscar 對未來所作的任何評論,均構成 1995 年《私人證券訴訟改革法》安全港條款所界定的前瞻性陳述。
Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our annual report on Form 10-K for the period ended December 31, 2025, and the quarterly report on Form 10-Q for the period ended June 30, 2026, each as filed with the Securities and Exchange Commission and other filings with the SEC, including our quarterly report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.
由於多項重要因素,實際結果可能與該等前瞻性陳述所示存在重大差異,包括我們截至 2025 年 12 月 31 日止期間的 Form 10-K 年度報告,以及截至 2026 年 6 月 30 日止期間的 Form 10-Q 季度報告(均已向美國證券交易委員會提交),以及向 SEC 提交的其他文件,包括我們截至 2026 年 9 月 30 日止期間的 Form 10-Q 季度報告(將向 SEC 提交)。
Such forward-looking statements are based on current expectations as of today. Oscar anticipates that subsequent events and developments may cause estimates to change. While the company may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
該等前瞻性陳述係基於截至今日的當前預期。Oscar 預期後續事件與發展可能導致估計發生變化。儘管公司未來可能選擇在某個時間點更新這些前瞻性陳述,但我們明確聲明不承擔任何更新義務。
The call will also refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in the third quarter earnings press release available on the company's Investor Relations website at ir.oscarhealth.com. We have not provided a quantitative reconciliation of estimated full year 2026 adjusted EBITDA as described in this call to GAAP net income because Oscar is unable without making unreasonable efforts to calculate certain reconciling items with confidence.
本次電話會議亦將提及若干非 GAAP 指標。這些指標與最直接可比的 GAAP 指標之調節表,載於公司投資人關係網站 ir.oscarhealth.com 上的第三季財報新聞稿。我們未就本次電話會議所述之 2026 全年調整後 EBITDA 估計提供量化的 GAAP 淨利調節,因為 Oscar 若不付出不合理的努力,無法有把握地計算若干調節項目。
With that, I will turn the call over to our CEO, Mark Bertolini.
接下來,我將把電話會議交給我們的執行長 Mark Bertolini。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Good morning. Thank you, Chris, and thank you all for joining us. 2026 is the strongest year in Oscar Health's history. We delivered record profitability for the first 9 months of the year, reporting earnings from operations of $1.3 billion and net income of $1.2 billion. We also expect to achieve several of our 2024 Investor Day commitments one year ahead of plan.
各位早安。謝謝你,Chris,也感謝各位加入我們。2026 年是 Oscar Health 歷史上最強勁的一年。我們在今年前 9 個月創下獲利新高,營業利益達 13 億美元,淨利達 12 億美元。我們也預期將比原計畫提前一年達成多項 2024 年投資人日承諾。
Based on our performance year-to-date, we are raising 2026 earnings from operations guidance for a third time to a range of $850 million to $950 million. Our strong third quarter performance exceeded our expectations with improvement across all core metrics. Revenue grew roughly 70% year-over-year to $5.1 billion.
基於我們年初至今的表現,我們第三次上調 2026 年營業利益指引至 8.5 億至 9.5 億美元區間。我們強勁的第三季表現超出預期,所有核心指標均有所改善。營收年增約 70% 至 51 億美元。
Our SG&A expense ratio improved 350 basis points year-over-year to 14%, another record low, reflecting the disciplined execution, greater fixed cost leverage and AI-driven efficiencies. MLR improved 450 basis points over the prior year period to 84%. Earnings from operations increased $307 million year-over-year to $178 million and adjusted EBITDA increased $308 million to $207 million.
我們的 SG&A 費用率較去年同期改善 350 個基點至 14%,再創歷史新低,反映出嚴謹的執行、更高的固定成本槓桿效益以及 AI 驅動的效率提升。醫療損失率(MLR)較去年同期改善 450 個基點至 84%。營業利益年增 3.07 億美元至 1.78 億美元,調整後 EBITDA 年增 3.08 億美元至 2.07 億美元。
Before I turn to our business highlights, I will share our perspective on current market trends. The ACA is the foundation of a rapidly developing individual market. Americans are building careers on their own terms. They are starting businesses, combining part-time work, participating in the gig economy and retiring early. More than 19 million people rely on the ACA, yet 28 million American workers remain uninsured.
在我談到業務亮點之前,我先分享我們對當前市場趨勢的看法。ACA 是快速發展的個人保險市場之基礎。美國人正以自己的方式打造職涯。他們創業、結合兼職工作、參與零工經濟並提早退休。超過 1,900 萬人依賴 ACA,但仍有 2,800 萬名美國勞工沒有保險。
Affordable coverage gives people greater financial security to pursue new opportunities and helps employers build a more stable workforce. Both parties understand health care is a priority for the American people. We have a significant opportunity to expand the ACA into a competitive marketplace that improves affordability and supports a resilient economy. Our 2026 performance demonstrates the strength of our operating model. We remain focused on growing market share and expanding margin in 2027.
可負擔的保險保障讓人們在追求新機會時擁有更高的財務安全感,也幫助雇主建立更穩定的勞動力。兩黨都理解醫療保健是美國人民的優先事項。我們有重大機會將 ACA 擴展為一個具競爭力的市場,提升可負擔性並支持具韌性的經濟。我們 2026 年的表現展現了我們營運模式的實力。我們仍專注於在 2027 年擴大市占並提升利潤率。
Our weighted average rate increase of approximately 14% for 2027 open enrollment period reflects elevated trend and higher market morbidity. Pricing is one lever of our growth model. We also target markets where our products and distribution network address consumer needs, including opportunities created by competitor exits. These strengths, combined with our medical cost management, operating efficiency and superior technology will drive sustainable financial performance in 2027 and beyond.
我們針對 2027 年開放投保期的加權平均費率調升約 14%,反映出較高的趨勢與更高的市場疾病嚴重度。定價是我們成長模式的一項槓桿。我們也鎖定那些我們的產品與通路網路能滿足消費者需求的市場,包括競爭對手退出所帶來的機會。這些優勢結合我們的醫療成本管理、營運效率與卓越科技,將推動 2027 年及以後的可持續財務表現。
Now I will review our business highlights. Oscar Insurance ended the third quarter with 2.7 million members, up 27% year-over-year. We are entering open enrollment with a 24% larger footprint spanning 713 counties. We are also expanding into South Carolina. Our expansion increases our total addressable market to approximately 10 million consumers across 21 states.
接下來我將回顧我們的業務亮點。Oscar Insurance 在第三季末的會員數達 270 萬人,年增 27%。我們以覆蓋範圍擴大 24% 的規模進入開放投保期,涵蓋 713 個郡。我們也正擴展至南卡羅來納州。此次擴張使我們的總可服務市場提升至約 1,000 萬名消費者,遍及 21 個州。
Oscar is launching a new wave of consumer lifestyle products. Our newest product, RetireEase, is live in select markets and serves a growing segment of 2.5 million early retirees in the ACA. Members keep their trusted doctors and receive set prices for preventative services, physical therapy and heart, bone and joint care. We are also addressing affordability through bundled benefits. Hundreds of Oscar plans now include dental and vision coverage.
Oscar 正推出新一波以消費者生活型態為導向的產品。我們最新產品 RetireEase 已在部分市場上線,服務 ACA 中持續成長的 250 萬名提早退休族群。會員可保留信任的醫師,並以固定價格獲得預防性服務、物理治療,以及心臟、骨骼與關節照護。我們也透過組合式福利來提升可負擔性。目前已有數百個 Oscar 方案納入牙科與視力保障。
In addition, our new Allstate Health Solutions partnership pairs Oscar plans with low-cost supplemental coverage to help bronze members manage out-of-pocket costs. Each product meets a distinct consumer need and extends our reach into high-value underserved segments. Our Oscar team is also scaling CHOICE. Our Hy-Vee Health with Oscar product is expanding from Iowa into Nebraska, Missouri and Kansas. This product's concierge care model earns a 92% satisfaction rate and can now serve more small businesses, part-time employees and gig workers.
此外,我們與 Allstate Health Solutions 的新合作,將 Oscar 方案與低成本補充保險搭配,協助青銅級(bronze)會員管理自付費用。每項產品都滿足不同的消費者需求,並擴大我們在高價值、服務不足族群中的觸及。我們的 Oscar 團隊也正在擴大 CHOICE 規模。我們的 Hy-Vee Health with Oscar 產品正從愛荷華州擴展至內布拉斯加州、密蘇里州與堪薩斯州。該產品的禮賓式照護模式獲得 92% 的滿意度,現在可服務更多小型企業、兼職員工與零工工作者。
We are also launching HelloMeno off-exchange to better serve women across the workforce. Employer demand is building. CHOICE adoption is growing fastest in health care, technology, construction and manufacturing sectors across Oscar states. Oscar's health technology puts consumer in control of their health care decisions across two platforms.
我們也將在交易所外(off-exchange)推出 HelloMeno,以更好地服務職場中的女性。雇主需求正在升溫。在 Oscar 覆蓋的各州中,CHOICE 的採用成長最快的產業為醫療保健、科技、建築與製造。Oscar 的健康科技透過兩大平台,讓消費者掌控其醫療保健決策。
The Oscar platform now includes new AI capabilities that make our product suite easy to understand. The Lucie platform serves the broader market, personalizing the health care shopping experience at scale. Lucie instantly matches consumers with plans from major ACA carriers and select supplemental carriers and guides broker through CMS eligibility.
Oscar 平台現已加入新的 AI 能力,使我們的產品組合更易於理解。Lucie 平台服務更廣泛的市場,以規模化方式個人化醫療保險的選購體驗。Lucie 可即時為消費者匹配主要 ACA 承保公司及特定補充保險承保公司的方案,並引導經紀人完成 CMS 資格判定。
No other platform brings these capabilities together in one place. Lucie is on track to sell approximately 800,000 new policies in 2027, driven by growing broker and consumer demand. Oscar Health's third quarter performance puts us on track to deliver strong results one year ahead of plan. Our disciplined pricing, product innovation and technology-powered support are delivering superior member experiences and efficiency across the company. The individual market opportunity is growing.
沒有任何其他平台能在同一處整合這些能力。在經紀人與消費者需求持續成長的帶動下,Lucie 預計在 2027 年銷售約 80 萬張新保單。Oscar Health 的第三季表現使我們有望提前一年交出強勁成果。我們嚴謹的定價、產品創新與科技驅動的支援,正在為會員帶來更優異的體驗,並提升全公司的效率。個人市場的機會正在擴大。
People expect health care to work like the best consumer products, simple, transparent and personalized. We are building a consumer health care company that meets those expectations and serves a much larger market. The team is positioned to grow market share and expand margin in 2027. We are also on track to deliver our long-term targets, including at least $4 earnings per share by 2029. Thank you to the Oscar Health team for giving people power over their health care.
人們期待醫療保健能像最好的消費性產品一樣運作:簡單、透明且個人化。我們正在打造一家以消費者為核心的醫療保健公司,以滿足這些期待並服務更大的市場。團隊已具備在 2027 年擴大市占並提升利潤率的有利位置。我們也正按計畫達成長期目標,包括在 2029 年前每股盈餘至少達到 4 美元。感謝 Oscar Health 團隊,讓人們掌握自身醫療保健的主導權。
With that, I will turn the call over to Scott. Scott?
那麼,我將把電話交給 Scott。Scott?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Thank you, Mark, and good morning, everyone. Sorry for the voice. I'm recovering from a cold today. Through the first 9 months of 2026, we delivered net income of approximately $1.2 billion or $3.59 per diluted share. Earnings from operations were approximately $1.3 billion. Based on these strong results and underlying trends, we are raising our full year 2026 outlook.
謝謝你,Mark,各位早安。抱歉聲音有點沙啞。我今天正在從感冒中恢復。在 2026 年前 9 個月,我們實現淨利約 12 億美元,或每股稀釋後盈餘 3.59 美元。營運收益約 13 億美元。基於這些強勁的結果與基本趨勢,我們上調 2026 全年展望。
Turning now to third quarter results. We ended the quarter with approximately 2.7 million members, an increase of 27% year-over-year. Sequential decline in membership primarily reflects disenrollments from CMS' industry-wide eligibility review, which was in line with expectations. From a second smaller CMS review, we expect a small number of additional disenrollments in the fourth quarter.
接著看第三季業績。本季末我們約有 270 萬名會員,年增 27%。會員數的季減主要反映 CMS 針對全產業的資格審查所導致的退保,符合我們的預期。針對第二次、規模較小的 CMS 審查,我們預期第四季還會有少量額外退保。
Total revenue increased approximately 70% year-over-year to $5.1 billion, driven by rate increases and higher membership. During the quarter, we received updated risk adjustment data. We saw significant improvement in Oscar's risk relative to the market and market morbidity was modestly favorable to our expectations.
總營收年增約 70% 至 51 億美元,主要由費率上調與會員數增加所帶動。本季我們收到更新的風險調整資料。我們看到 Oscar 的風險相對於市場有顯著改善,而市場疾病嚴重度(morbidity)也略優於我們的預期。
These factors drove a $250 million revenue benefit in the quarter. Risk adjustment as a percentage of premiums was 11.8% in the third quarter and 17.2% through the first 9 months. While the additional data gives us greater visibility and more confidence in our risk adjustment accruals, we continue to take a cautious approach to our risk adjustment reserves.
這些因素在本季帶來 2.5 億美元的營收利多。第三季風險調整占保費比重為 11.8%,前 9 個月累計為 17.2%。雖然新增資料讓我們對風險調整應計項目有更高能見度與信心,我們仍持續對風險調整準備金採取審慎作法。
The third quarter medical loss ratio was 84%, an improvement of 450 basis points year-over-year. Improvement was primarily driven by our disciplined pricing strategy. Overall, year-to-date utilization was moderately favorable to our expectations. By category, inpatient, professional and pharmacy utilization were favorable, while outpatient was elevated.
第三季醫療損失率(MLR)為 84%,年減 450 個基點。改善主要來自我們嚴謹的定價策略。整體而言,年初至今的使用量(utilization)略優於我們的預期。按類別來看,住院、專業服務與藥局使用量表現有利,而門診使用量偏高。
We believe some of the elevated outpatient utilization reflects a rotation from inpatient to outpatient care, driven in part by our affordability initiatives. Switching to administrative costs. The third quarter SG&A expense ratio was 14%, the lowest in the company's history. The approximately 350 basis point year-over-year improvement was driven by lower risk adjustment as a percentage of premium, higher fixed cost leverage and disciplined expense management, including an increasing impact from technology and AI initiatives.
我們認為,部分偏高的門診使用量反映了照護從住院轉向門診的輪動,部分原因是由我們的可負擔性(affordability)措施所推動。接著談管理成本。第三季 SG&A 費用率為 14%,為公司史上最低。年減約 350 個基點,主要由保費中風險調整占比下降、更高的固定成本槓桿,以及嚴謹的費用管理所帶動,其中也包括科技與 AI 計畫影響力持續提升。
We reported earnings from operations of $178 million in the third quarter, a $307 million year-over-year improvement. Operating margin was 3.5%, an improvement of approximately 780 basis points year-over-year. Net income was $167 million, a $305 million increase year-over-year. Adjusted EBITDA was $207 million in the quarter, an increase of $308 million year-over-year.
我們第三季營運收益為 1.78 億美元,年增 3.07 億美元。營業利益率為 3.5%,年增約 780 個基點。淨利為 1.67 億美元,年增 3.05 億美元。本季調整後 EBITDA 為 2.07 億美元,年增 3.08 億美元。
Shifting to the balance sheet. We ended the third quarter with approximately $9 billion of cash and investments, including $360 million of cash and investments at the parent. The sequential decline in cash and investments primarily reflect the payment of our 2025 risk adjustment payable during the third quarter. As of September 30, our Insurance subsidiaries had approximately $2.3 billion of capital and surplus, including $1.4 billion of excess capital, which was driven by our strong operating performance.
接著看資產負債表。第三季末我們約有 90 億美元的現金與投資,其中母公司層級的現金與投資為 3.6 億美元。現金與投資的季減主要反映我們在第三季支付了 2025 年應付的風險調整款項。截至 9 月 30 日,我們的保險子公司約有 23 億美元的資本與盈餘,其中包含 14 億美元的超額資本,主要由強勁的營運表現所驅動。
Turning now to our 2026 full year guidance. Based on our results through the first 9 months, we are raising our full year earnings from operations guidance to a range of $850 million to $950 million. At the midpoint, this is $200 million above our prior outlook and $550 million above our original guidance. Our improved outlook reflects favorable risk adjustment and utilization that was moderately favorable to our expectations.
接著談 2026 全年指引。基於前 9 個月的表現,我們將全年營運收益指引上調至 8.5 億至 9.5 億美元區間。以中位數計,較先前展望高出 2 億美元,較最初指引高出 5.5 億美元。展望上修反映風險調整有利,以及使用量略優於我們的預期。
We now expect total revenue in the range of $19 billion to $19.3 billion, an increase of $300 million from our prior outlook. We expect to end the year with approximately 2.5 million members, which reflect the additional disenrollments from the second CMS review. We expect risk adjustment as a percentage of premiums to be between 17% and 18% compared with our prior expectation of 20%, which is based on year-to-date risk adjustment experience.
我們目前預期總營收介於 190 億至 193 億美元,較先前展望增加 3 億美元。我們預期年底會員數約為 250 萬名,反映第二次 CMS 審查帶來的額外退保。我們預期風險調整占保費比重介於 17% 至 18%,低於先前預期的 20%,此係基於年初至今的風險調整經驗。
Turning to the medical loss ratio. We now expect a full year MLR in the range of 80.5% to 81.5%. On administrative expenses, we expect our SG&A expense ratio to be in the range of 15.1% to 15.6%. We expect adjusted EBITDA to be roughly $110 million higher than earnings from operations. Our performance this year positions us well for 2027. We will provide formal guidance on the fourth quarter earnings call, but let me spend a moment on our buying assumptions.
接著談醫療損失率。我們目前預期全年 MLR 介於 80.5% 至 81.5%。在管理費用方面,我們預期 SG&A 費用率介於 15.1% 至 15.6%。我們預期調整後 EBITDA 將比營運收益高出約 1.1 億美元。我們今年的表現讓我們在 2027 年具備良好基礎。我們將在第四季財報電話會議提供正式指引,但先花一點時間談談我們的投保(buying)假設。
We expect overall ACA marketplace membership to be stable compared with year-end 2026, and we are positioned to gain market share. We continue to take a disciplined approach into pricing, balancing growth and profitability. As Mark mentioned, our weighted average rate increase for 2027 is approximately 14%. Our pricing reflects an incremental increase in medical cost trends and higher market morbidity from ongoing program integrity initiatives.
我們預期整體 ACA 市集會員數相較 2026 年底將維持穩定,而我們已做好取得市占的準備。我們持續採取嚴謹的定價方式,在成長與獲利之間取得平衡。如 Mark 所提,我們 2027 年加權平均費率調升約為 14%。我們的定價反映醫療成本趨勢的增量上升,以及因持續推動計畫完整性(program integrity)措施而帶來較高的市場疾病嚴重度。
Our competitive positioning, differentiated products and strong member experience gives us confidence as we head into 2027. We expect improved medical cost performance and administrative efficiency to drive further margin expansion next year. In closing, we are on track to deliver a strong financial performance in 2026, and we remain focused on driving sustainable earnings growth and achieving our long-term target of at least $4 of earnings per share by 2029.
我們的競爭定位、差異化產品與強勁的會員體驗,讓我們對邁向 2027 年充滿信心。我們預期醫療成本表現改善與管理效率提升,將在明年推動利潤率進一步擴張。最後,我們有望在 2026 年交出強勁的財務表現,並將持續專注於推動可持續的獲利成長,達成我們的長期目標:在 2029 年前每股盈餘至少達到 4 美元。
With that, I'll turn the call over to the operator for the Q&A portion of our call.
那麼,我將把電話交給接線員,進入問答環節。
Operator
Operator
(Operator Instructions)
(接線員指示)
Andrew Mok, Barclays.
Andrew Mok,Barclays。
Andrew Mok - Analyst
Andrew Mok - Analyst
G&A came in meaningfully better in the quarter, but updated guidance appears to imply a 400 basis point sequential increase. Can you elaborate on the drivers of the strong 3Q outperformance? And what's driving the higher-than-normal step-up for 4Q?
本季 G&A 明顯優於預期,但更新後的指引似乎暗示第四季將季增 400 個基點。能否說明第三季強勁超預期的驅動因素?以及第四季為何會出現高於常態的上升幅度?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
So on SG&A, I think that in Q3, you're seeing the benefit of our continuous disciplined expense management, growing impact of AI that we're deploying across the business and those are the themes that I would call out. We're also picking up a pretty healthy amount of fixed cost leverage. So that -- those are the drivers of Q3 performance.
關於 SG&A,我認為在第三季你看到的是我們持續嚴謹的費用管理所帶來的效益,以及我們在全公司部署的 AI 影響力日益擴大——這些是我想強調的主軸。我們也獲得相當可觀的固定成本槓桿效益。所以——這些就是第三季表現的驅動因素。
As you think about Q4, there is a step-up in the Q4 SG&A ratio. A portion of that is being driven by things like -- I would say these are Q4 specific spend, things like OE ramp, some of our risk adjustment operations where we do a lot of our chart collection activity in the fourth quarter. And then we've got some typical investments that we make for '27 growth in the fourth quarter. So I would say these are kind of seasonally expected spend, but we like the trajectory of SG&A.
至於第四季,第四季 SG&A 比率會上升。其中一部分是由一些——我會說這些是第四季特定支出所驅動,例如 OE 的爬坡(ramp),以及我們的部分風險調整作業——我們在第四季會進行大量病歷(chart)收集活動。此外,我們在第四季也會進行一些典型投資,以支持 2027 年的成長。因此我會說這些屬於季節性、符合預期的支出,但我們喜歡 SG&A 的走勢。
Andrew Mok - Analyst
Andrew Mok - Analyst
Great. And I think I heard you say membership is expected to be stable with year-end 2026 results while you take market share. Can you flesh out a little bit more how you're thinking about your share gains in the context of how market growth might play out for 2027?
了解。我想我聽到你說,會員數預期將與 2026 年底的結果大致持平,同時你們會取得市占。能否再多談一些,你們如何在 2027 年市場可能的成長情境下,思考你們的市占提升?
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Sure. Thanks, Andrew. This is Mark. So we'll start with the market growth that both Scott and I highlighted, where we've -- we're now going to be 713 markets. We've added South Carolina.
當然。謝謝你,Andrew。我是 Mark。那我們先從我和 Scott 都強調過的市場成長開始,也就是我們——我們現在將會有 713 個市場。我們新增了南卡羅來納州。
Secondly, I would offer new program extensions and products into the marketplace like RetireEase, where we tend to have very high retention and opportunistic growth in those marketplaces.
第二,我會提到把新的方案延伸與產品帶進市場,例如 RetireEase;在這些市場中,我們通常有非常高的留存率以及機會型成長。
And then finally, there's about 850,000 lives coming to market as a result of competitor exits. So all of that, as we add that into our mix and our ability to price appropriately disciplined and competitively in the marketplace, we believe that we'll pick up share.
最後,因競爭對手退出,約有 85 萬名承保人數將進入市場。因此,當我們把這些納入我們的組合,並且能在市場上以適當的紀律與具競爭力的方式定價時,我們相信我們會提升市占。
Operator
Operator
Jessica Tassan, Piper Sandler.
Jessica Tassan,Piper Sandler。
Jessica Tassan - Analyst
Jessica Tassan - Analyst
Congratulations on the phenomenal results. So our estimates imply, I think, that year-over-year MedEx PMPM increased 19.9% in 3Q from down 1.5% in 2Q. So can you maybe just give us some color on the utilization behavior you're observing by metal level? Curious to know how MLR seasonality is evolving both for bronze members and then also whether you're observing any changes in silver member to your historical -- relative to historicals or relative to expectations and why that might be?
恭喜你們取得非凡的成果。我們的估算顯示,我想 MedEx 的 PMPM 年增率在第三季(3Q)為 19.9%,而第二季(2Q)則是下滑 1.5%。所以你們能否就你們觀察到的、按金屬層級(metal level)區分的使用率行為提供一些說明?也想了解 MLR 的季節性在青銅(bronze)會員方面如何演變,以及你們是否觀察到白銀(silver)會員相較於歷史——相較於歷史水準或相較於預期有任何變化,以及可能原因?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes, Jess. Let me start with the claims PMPM. So one of the challenges that you guys have this year in looking at claims PMPM is that we do have our member months because of some of these CMS-driven disenrollments. Member months are -- reported are a little bit different than those that are actually generating claims. So there is a little bit of a skew in that.
好的,Jess。我先從理賠 PMPM 談起。今年你們在看理賠 PMPM 時的一個挑戰是,我們的會員月數(member months)因為一些 CMS 主導的退保(disenrollments)而受到影響。所報告的會員月數——與實際產生理賠的會員月數有些不同。因此會有一些偏差。
So when I unpack that and kind of put Humpty Dumpty back together, what I see is that from Q1 to Q2, there's a meaningful step-up in claims PMPM. We see another step-up in Q3 from there. And in Q4, we're anticipating, and this has historically been the case that there's less movement, a fairly stable Q3 to Q4 PMPM support.
所以當我把這些拆開來看、再把整體拼回去時,我看到的是:從第一季到第二季,理賠 PMPM 有顯著的上升。我們在第三季又在此基礎上再上了一階。而在第四季,我們預期——而且歷來通常如此——變動會比較小,第三季到第四季的 PMPM 會相對穩定、形成支撐。
When I look at utilization, we're seeing utilization across the metals, which is consistent with the risk that we see there. We're not seeing any specific thing that I would call out from one metal to the next. I think that the risk that we have in the book is being supported by the claims that we're seeing. And we're -- as you think about the MLR that we've got embedded for our fourth quarter, we are expecting a normal seasonal uptick in MLR into the fourth quarter from where we are in Q3.
就使用率而言,我們看到各金屬層級的使用率表現與我們所看到的風險一致。我們沒有看到任何我會特別點名、在某一金屬層級相較另一層級特別突出的現象。我認為我們保單組合中的風險,正被我們看到的理賠所支持。而且——當你們思考我們在第四季所內含的 MLR 時,我們預期 MLR 會從第三季的水準在第四季出現正常的季節性上升。
Jessica Tassan - Analyst
Jessica Tassan - Analyst
Got it. That's really helpful. And then I appreciate that the midterm has changed the eAPTC outlook considerably for '28, but maybe hoping you can help us better understand just the membership outlook for 2027. Where are we in terms of CMS' fraud and marketplace integrity efforts? And how do you expect those efforts to evolve in '27? And then can you just clarify that despite the expectation for flat enrollment year-over-year in 2027, you all are priced for an increase in market morbidity within that 14%.
了解。這非常有幫助。另外,我理解期中選舉已大幅改變 2028 年 eAPTC 的展望,但希望你們能協助我們更好理解 2027 年的會員數展望。就 CMS 的詐欺與市場完整性(marketplace integrity)措施而言,我們目前進展到哪一步?你們預期這些措施在 2027 年會如何演變?另外也請你們澄清:儘管預期 2027 年投保人數年對年持平,你們在那 14% 的定價中仍已反映市場疾病率(morbidity)上升的假設?
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Yes, Jess, I'll start, and then I'll turn it over to -- I'll turn it over to Scott on market morbidity. So we do expect stable membership year-over-year. We do still see more program integrity programs coming through. We believe that will have an impact on the marketplace. Obviously, as I said before, it's going to be offset by some of the other things, new markets entered, new products and other competitors leaving.
好的,Jess,我先回答,然後我會把市場疾病率的部分交給——我會交給 Scott。我們確實預期會員數年對年維持穩定。我們仍看到更多的方案完整性(program integrity)計畫陸續推出。我們相信這會對交易市場(marketplace)產生影響。當然,如我先前所說,這會被其他因素所抵銷,例如進入新市場、推出新產品,以及其他競爭對手退出。
So overall, we see the whole market being relatively stable. I don't think the midterms are going to have much of an effect, if anything, in the near term because there's a lot of bargaining that would need to go on given that the administration still will hold the veto pen.
因此整體而言,我們認為整個市場會相對穩定。我不認為期中選舉在短期內會有太大影響(如果有的話),因為在政府仍握有否決權的情況下,還需要進行大量協商。
And so getting the kind of things we would need to get done to, for example, reintroduce enhanced subsidies and others would have to be part of a grander deal, and we're not quite sure how the dynamics of that will move forward. We always plan for these things in our operating plans and risks and opportunities. And we always see what we would need to do should these things begin to happen. But right now, I don't know that much of anything is going to happen over the next year at least. Scott?
因此,要推動我們需要完成的事項——例如重新引入加強補貼(enhanced subsidies)等——必須納入更大型的整體協議之中,而我們也不太確定這些動態將如何往前推進。我們一向會在營運計畫中規劃這些事項,並評估風險與機會。我們也一直在思考,一旦這些事情開始發生,我們需要採取哪些行動。但就目前而言,我不確定未來至少一年內會有太多事情發生。Scott?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. So Jess, with respect to market morbidity, I have a couple of thoughts there. One is, we are seeing and expecting to see a stable ACA in '27. A lot of the big change events happened in '26, and we expect fewer going into '27. We are expecting that program integrity will have an impact, and we have built that into our pricing.
是的。Jess,關於市場疾病率,我有幾點想法。第一,我們看到並預期 2027 年 ACA 市場將維持穩定。許多重大變動事件發生在 2026 年,我們預期進入 2027 年後會少一些。我們預期方案完整性會帶來影響,而我們已將其納入定價。
So I would comment that on our average 14% rate increase, the three things that are really driving that 14% kind of in rank order of impact, number one is trend, which is in the, call it, high single digits and then market morbidity coverage is second. And then we also have built in a little bit of margin expansion into pricing. So we feel like we've got a very competitive price and some really terrific products in markets. So we're optimistic about our ability to grow share next year.
因此我會評論:就我們平均 14% 的費率調升而言,真正推動這 14% 的三個因素(按影響程度排序)是:第一是趨勢(trend),大約在高個位數;第二是市場疾病率/保障範圍(market morbidity coverage);第三,我們也在定價中納入了一點點利潤率擴張。所以我們覺得我們的價格非常有競爭力,而且在各市場也有一些非常出色的產品。因此我們對明年提升市占的能力感到樂觀。
Operator
Operator
Parker Snure, Raymond James.
Parker Snure,Raymond James。
Parker Snure - Analyst
Parker Snure - Analyst
Yes. So just kind of piggybacking on the previous few questions. Just curious on your view for this annual enrollment period. There's some additional friction that's being added to the enrollment process, some enhanced social security verification, broker consent, tax verification, things like that.
是的。那我就延續前面幾個問題。想請教你們對今年年度投保期(annual enrollment period)的看法。投保流程增加了一些額外摩擦,例如更強化的社會安全號驗證、經紀人同意、稅務驗證等等。
I understand that you think the market will be flat, but just curious if you view these procedural measures as being a material driver in this year's annual enrollment process? And could this lead to some people being thrown off? And I guess just kind of general expectations in terms of market morbidity. I know you touched on that, but just related to that specific dynamic.
我理解你們認為市場會持平,但想請教你們是否認為這些程序性措施會成為今年年度投保流程中的重要驅動因素?這是否可能導致一些人被「刷掉」?另外也想請教關於市場疾病率的整體預期。我知道你們已經提到過,但想針對這個特定動態再請你們說明。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Parker, I'll start by describing -- obviously, we've had a lot of preparation to try and get in front of the things for brokers in the enrollment program this year. So it will slow down the start. These systems are new to them. We did a lot of training over the summer. We even built our own capabilities on our own platform to help them as they navigate through this.
Parker,我先說明——很明顯地,我們為了今年的投保計畫中與經紀人相關的事項,做了大量準備,試圖提前因應。所以一開始會放慢速度。這些系統對他們來說是新的。我們在夏天做了很多訓練。我們甚至在自家平台上建立了自己的功能,協助他們在操作過程中順利應對。
But there will be a learning curve. It will be something new for them, and it will have an impact on their productivity. But I think that is something that they will pick up quickly enough. We're watching it every day and watching how it evolves. And obviously, we only have four or five days under our belt anyway from the standpoint of enrollment. Scott, do you want to talk about market morbidity?
但確實會有學習曲線。這對他們來說是新事物,會影響他們的生產力。不過我認為他們會很快上手。我們每天都在觀察、看它如何演變。而且就投保的角度來看,我們也才剛開始四、五天而已。Scott,你要談談市場疾病率嗎?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. I would maybe call out two things. So first of all, just to reiterate, we're expecting that '27 will be flat to year-end '26. We do expect that some of these enhanced eligibility checks will result in some of the membership from '26 not being able to continue into '27. But we also anticipate that we're going to see a continuation of new people coming into the marketplace. We saw that in '26. We expect to see similar types of drivers for '27. So net-net, we expect the market overall to be flat to the '26 standpoint.
是的。我可能會特別點出兩件事。首先,重申一下,我們預期 2027 年將與 2026 年底持平。我們確實預期,部分加強的資格審查將導致 2026 年的一些會員無法延續到 2027 年。但我們也預期會持續有新的人進入市場。我們在 2026 年看到了這一點。我們預期 2027 年也會看到類似的驅動因素。因此,整體而言,我們預期市場相較 2026 年將大致持平。
Parker Snure - Analyst
Parker Snure - Analyst
Okay. That's super helpful. And if I can just get one more. Just curious on the fourth quarter guidance as it pertains to medical costs and MLR, it appears that it implies actually a decline in actual medical costs sequentially. I understand you'll have fewer members in the fourth quarter.
好的。這非常有幫助。如果我可以再問一個。我想了解一下第四季指引中與醫療成本和 MLR 相關的部分,看起來它其實暗示實際醫療成本會季比下降。我理解你們第四季的會員數會更少。
But if I look back over the last five years or so, I don't know if 4Q medical costs have actually declined sequentially ever. So just curious if you can give more color on that dynamic, if there were some onetime items in the third quarter or fourth quarter? Or is it just simply lower enrollment that's driving that?
但如果我回看過去大約五年,我不確定第四季醫療成本是否曾經出現過季比下降。所以想請教你能否多補充一些這個變化的原因:第三季或第四季是否有一次性項目?還是只是單純由較低的投保人數所驅動?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. I think you and I probably don't have the same math because when I look at implied fourth quarter MLR, it's in the range of, let's call it, low 90s. And we finished the third quarter with an MLR of 84%. If you add back PPD, that gets you to something like 84.8%. I think it's important when you think about the $250 million benefit of risk adjustment, all of that doesn't fall to the bottom line.
是的。我想你和我可能算出來的數字不一樣,因為我看第四季隱含的 MLR 大約在,我們姑且說,90% 出頭的區間。而我們第三季的 MLR 是 84%。如果把 PPD 加回去,大概會到 84.8% 左右。我認為在你思考風險調整帶來的 2.5 億美元效益時,很重要的一點是,這些並不會全部落到淨利。
It comes with claims. And so the -- you really -- you shouldn't be taking the risk adjustment out of the numbers. Like I think that's fundamental to the business, and it is offsetting the actual claims volumes that we're getting. So I think of -- if you want to think of a comparison, I would say I would start with an MLR in the third quarter of roughly 84.8%.
它是伴隨理賠一起發生的。因此——你真的——不應該把風險調整從數字裡拿掉。我認為那是這個業務的基本要素,而且它正在抵銷我們實際承受的理賠量。所以如果你想做比較,我會說先從第三季約 84.8% 的 MLR 開始看。
And you can add a couple of points, if you want to kind of say some of that favorable risk adjustment related to the first half of the year. But from there, it is still a step-up into Q4 based on everything we're seeing around people reaching their maximum out-of-pockets, utilization, that continues to be favorable to our expectations. We feel like the step-up in Q4 MLR makes sense to us and is consistent with the trends we're seeing through this part of the year.
如果你想的話,可以再加上幾個百分點,算是把上半年一些與風險調整相關的有利因素納入。但從那裡開始,依據我們看到的情況,第四季仍然會上升,因為人們達到自付額上限、使用率等因素,而這些表現仍優於我們的預期。我們認為第四季 MLR 的上升對我們而言是合理的,且與我們在今年截至目前所看到的趨勢一致。
Operator
Operator
Stephen Baxter, Wells Fargo.
Stephen Baxter,富國銀行。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
Kind of a similar theme question. So you're lowering the risk adjustment payable expectation by 200 basis points or 300 basis points. You're improving the MLR by 50 basis points. And then you're pointing to medical costs that I think that you're saying are modestly favorable to your expectations. So it seems like there's a pretty big difference there. And I know that you're a conservative company. But just thinking about the difference between those two items, if you could maybe help us bridge that, that would be super helpful.
也是類似主題的問題。所以你們把風險調整應付金的預期下調了 200 個基點或 300 個基點。你們把 MLR 改善了 50 個基點。然後你們提到醫療成本,我理解你們是說相對你們的預期略為有利。所以看起來兩者之間差距蠻大的。我也知道你們是一家偏保守的公司。但就這兩個項目之間的差異來看,如果你能幫我們把這中間的橋接說清楚一些,會非常有幫助。
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. So Steve, I would say a few things. So we have $250 million of favorable risk adjustment. And then we've got $45 million of PPD. As I talked about, not all of that favorable risk adjustment drops to the bottom line. There's a portion that's being offset by claims, which are appropriate given the risk of the book but are creating higher claims costs for us.
是的。所以 Steve,我會說幾點。我們有 2.5 億美元的有利風險調整。另外還有 4,500 萬美元的 PPD。正如我提到的,並不是所有有利的風險調整都會直接落到淨利。其中有一部分會被理賠所抵銷;這些理賠在承保組合風險下是合理的,但也會為我們帶來較高的理賠成本。
When I think about full year guidance that we just put out, I would say we're being -- we've only got Wakely through July. We're being prudent in making sure that we are thoughtful about the continued morbidity risk that's inherent in this marketplace. We feel like we have more than adequately covered for that in the guidance, and we're walking into good news. So we feel like we've got a very balanced target for full year operating earnings.
當我看我們剛發布的全年指引時,我會說我們是——我們目前只拿到 Wakely 到 7 月的資料。我們採取審慎態度,確保我們對這個市場內在的持續罹病率(morbidity)風險保持周全考量。我們覺得在指引中已經對此做了非常充分的覆蓋,而我們現在正迎來好消息。所以我們認為全年營運盈餘的目標設定非常平衡。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
Got it. Okay. And then, yes, I'd just be curious on your latest thinking on the latest CMS regulation governing 2028 open enrollment. I mean I think this was mostly codifying changes that were already made by OB3. But I would just love your feedback on that potential dynamic around maybe having less of an ability to utilize auto enrollments in 2028.
了解。好的。另外,我也想了解你們對最新 CMS 規範(針對 2028 年開放投保)的最新看法。我的意思是,我認為這多半是在把 OB3 已經做出的變更編纂成規。但我很想聽聽你們對於 2028 年可能較難使用自動續保(auto enrollments)這個潛在影響的看法。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Yes. Steve, we're working on that for our 2027 plan, and we'll prepare ourselves to handle those new provisions and believe it's in the guidance that -- it will be in the guidance that we provide going forward. But it's just -- from our perspective, program integrity is really important because it stabilizes the risk pool. And we want to keep those programs moving forward.
是的,Steve,我們正在把這些納入 2027 年的計畫中,並會做好準備來因應那些新條款;我們也相信這會反映在——會反映在我們未來提供的指引中。但從我們的角度來看,計畫完整性(program integrity)非常重要,因為它能穩定風險池。我們希望這些計畫能持續推進。
Our biggest fear is that we make sure that the people who should be excluded are excluded and that the people who need coverage get coverage. And so that work with CMS, because the sort of eligibility and enrollment responsibilities are split between CMS and the plans, we have to make sure that our data synchronizes.
我們最大的擔憂是要確保該被排除的人確實被排除,而需要保障的人能獲得保障。因此,與 CMS 的這項工作——因為資格與投保的責任在 CMS 與保險計畫之間是分拆的——我們必須確保我們的資料能同步。
And so in our latest review of this information, we have information going back and forth between CMS and us, and I'm sure our competitors as well and say, well, wait a minute, let's look at this population and talk about what you see versus what we see and what we need to do to make sure these people, if they are eligible, get access to coverage.
所以在我們最近一次對這些資訊的檢視中,我們與 CMS 之間(我相信競爭對手也是)有資料往返,我們會說,等一下,我們來看看這個族群,談談你們看到的與我們看到的有何不同,以及我們需要做什麼,才能確保這些人如果符合資格,就能取得保障。
So that's an ongoing, I would call it, a flaw in the system is that we have dispersed eligibility too far between plans and CMS. You don't see that much anywhere else. And so we're working through those changes as we go through program integrity. But we support program integrity and we believe it's important.
所以這是一個持續存在的——我會稱之為——系統缺陷:我們把資格認定分散在保險計畫與 CMS 之間,分散得太開。你在其他地方很少看到這種情況。因此,我們在推動計畫完整性的同時,也在逐步處理這些變更。但我們支持計畫完整性,並且相信它很重要。
Operator
Operator
Scott Fidel, Goldman Sachs.
Scott Fidel,高盛。
Scott Fidel - Analyst
Scott Fidel - Analyst
Mark, I thought it might be helpful just given the midterm elections results yesterday. If you want to, one, talk us through like in terms of as -- now as you go to the hill and sort of speak with members and the expanded Blue Caucus, from a policy perspective, what, in particular, you'll maybe be advocating for the ACA? I know that in the prepared comments, you talked about opportunity to expand the ACA.
Mark,我想鑑於昨天期中選舉的結果,或許談一下會很有幫助。如果你願意的話,第一,當你現在去國會山莊,並與議員以及擴大的 Blue Caucus 交流時,從政策角度來看,針對 ACA,你特別可能會倡議哪些事項?我知道在事先準備的發言中,你提到有機會擴大 ACA。
But just curious in terms of -- is it -- I don't think it's probably as simple as you'll just advocate for sort of renewing the enhanced subsidies. I would assume that there's probably suggestions that you want to make as well around strengthening the foundation of the program longer term. And then from a timing perspective, do you think that '28 would be possible in terms of potentially getting the subsidies restored? Or curious just on your thoughts on timing as the Congress sort of start to '27.
但我想了解的是——我不認為事情會簡單到你們只會倡議延長加強版補貼。我猜想你們可能也會就如何在更長期強化該計畫的基礎提出一些建議。另外就時程而言,你認為在 2028 年有可能讓補貼恢復嗎?或者想請教你對時程的看法,因為國會將在 2027 年開始運作。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
So I think the first thing, Scott, you should know is that we have been working both at the state level and at the federal level. And we've actually made a lot of progress at the state level around things like CHOICE, and -- I mean, at the state level versus federal. And at the federal level, we've been pushing through CMS and through the administration ideas about how do we best support the changes that we need to make to make the ACA TAM bigger.
所以 Scott,我認為你首先應該知道的是,我們一直同時在州層級與聯邦層級推動相關工作。而且我們其實在州層級已經取得不少進展,例如在 CHOICE 這類事項上——我的意思是,在州層級相對於聯邦層級。而在聯邦層級,我們一直透過 CMS 以及行政部門推動一些想法:我們要如何最好地支持必要的變革,以便把 ACA 的 TAM(可服務總市場)做得更大。
And part of that is this whole eligibility issue. How do we get that right? And one of our suggestions has been that we create wallets, enhanced HSAs, if you will, that will allow people by having KYC criteria will allow them to be more sure of eligibility as people come into the program. We can stabilize that piece of the business that does great things for the risk pool and for growth and for our distribution channel that has to work through all these issues.
其中一部分就是整個資格認定的問題。我們要如何把這件事做對?我們的一項建議是建立錢包(如果你願意,也可稱為強化版 HSA),透過設定 KYC(認識你的客戶)標準,讓人們在加入計畫時能更有把握其資格符合要求。我們可以穩定這一塊業務,這對風險池、成長以及我們必須穿越所有這些議題的分銷通路都會帶來很大的正面效果。
Piecemeal every so often, as it has happened over the last couple of years is difficult. On the enhanced subsidies, we shall see. That's a financial discussion. We shall see how much of that comes back in. Will it change in form? It's going to have to be a deal before '28 between the administration and the new caucus. And we don't know how that's going to work.
像過去幾年那樣,時不時零碎地調整,是很困難的。至於加強補貼,我們拭目以待。那是一個財務層面的討論。我們會看看有多少會回來。形式會改變嗎?在 '28 之前,政府與新的黨團之間必須達成協議。而我們不知道那會如何運作。
The President has made comments that he can work with the caucus. We have -- the caucus has been talking about the things that they want to have happen. We need to see how that relationship is actually going to work and evolve into legislation and then regulation. So I'm not holding out a whole lot in '27 toward '28 at this moment other than we will keep going forward.
總統曾表示他可以與該黨團合作。我們——該黨團一直在談他們希望發生的事情。我們需要看看那段關係實際上會如何運作,並如何演變成法案,接著再變成法規。所以就目前而言,我對 '27 走向 '28 不抱太大期待,除了我們會持續向前推進。
We continue to work with the administration on working on the eligibility piece. And on regulations like tax treatment for HSA purchases and defined contribution for employers, where we see a huge opportunity if we can clear some of that road blockage out of the way for them in the future. That makes the TAM bigger. That makes the ACA framework work.
我們持續與政府合作,處理資格認定這一塊。也包括像是 HSA 購買的稅務處理、以及雇主的確定提撥(defined contribution)等法規議題;如果未來能替他們清除一些道路障礙,我們看到巨大的機會。那會讓 TAM(可服務總市場)變大。也會讓 ACA 架構更能運作。
And we've also been talking to the Democrats as well while we've been talking to the administration about what we could do to make CHOICE a reality. In a lot of ways, my point of view is that what we are talking about in making a bigger individual market is very much what some of the aims of the ACA were in its initial construction. So I think we have a lot of common ground there. It could be a great place for both parties to get together and actually do something that could advantage the American public and more importantly, our economy.
此外,在與政府討論如何讓 CHOICE 成為現實的同時,我們也一直在與民主黨方面溝通。在很多方面,我的觀點是:我們所談的、讓個人市場變得更大的方向,其實非常符合 ACA 在最初設計時的一些目標。所以我認為我們在這方面有很多共同點。這可能會是一個很好的契機,讓兩黨走到一起,真正做出一些能讓美國大眾受益、而更重要的是能讓我們經濟受益的事情。
Scott Fidel - Analyst
Scott Fidel - Analyst
That's helpful. And for my follow-up question, I wanted to toggle just over to pricing and it sounds like the average rate increases that you talked about are right in line with the market. I'm curious just from the average perspective, obviously, every pricing MSA is going to be different. But sort of a general sort of breakdown as you think about those sort of mid-teens, 14% or so sort of pricing, how are you -- how would you say that sort of breaks down between like underlying cost trend versus morbidity versus any other sort of key actuarial underwriting factors? And that's it for me.
這很有幫助。至於我的追問,我想把話題切換到定價;聽起來你提到的平均費率調升幅度與市場大致一致。我好奇從平均的角度來看,當然每個定價 MSA 都會不同。但就你所說的那種約 14%、大概落在十幾%的定價,整體上你會怎麼拆解:例如基礎成本趨勢、疾病率(morbidity),以及其他關鍵的精算核保因素,各自大概貢獻多少?我就問到這裡。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
I'll start off and then I'll pass it to Scott on the morbidity stuff. So the very basis of our network -- of our pricing structure and our plan design in every market starts with the network. And so where we have a great network relationship, and where we can -- again, all the most successful players in the ACA use narrow networks. And so you get a discount and that passes through to the customer, number one.
我先開頭,然後把疾病率的部分交給 Scott。所以,我們在每個市場的網路——也就是我們的定價結構與方案設計——最根本的起點是醫療網路(network)。因此,當我們有很好的網路合作關係,而且我們能——再次強調,ACA 裡最成功的參與者都使用窄網路(narrow networks)。這樣你就能拿到折扣,並把折扣回饋給客戶,這是第一點。
Number two, what are your distribution relationships like? And what can you rely on in getting distribution done? Those are the two first most important requirements we assess when we go into the market. And then we look at the competitive framework, the pricing tolerance in the marketplace and then we build our models.
第二,你的分銷合作關係如何?你在推動分銷時能依賴什麼?這是我們進入市場時評估的前兩個最重要條件。接著我們會看競爭格局、市場對定價的容忍度,然後建立我們的模型。
But think of it as us underwriting that network and distribution model first as a way of deciding where our price points need to be in the market. Relative to morbidity and the intricacies of pricing, Scott, I'll just toss it over to you to add anything that you would.
但你可以把它想成:我們先對網路與分銷模式進行核保,藉此決定我們在市場中的價格點應該落在哪裡。至於疾病率與定價的細節,Scott,我就把球丟給你,看看你要補充什麼。
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. Scott, a few other thoughts. So first off, we are starting from a position of strength in '26. Our relative price increase this year was probably a bit lower than some of our competitors. So we've already got a very advantaged price position, then you go to a 14% price increase from there. So we think that from a competitive position, our pricing looks -- as you said, it's an MSA by MSA game, but we like how we look on the book in aggregate.
好的。Scott,再補充幾點想法。首先,我們在 '26 是從一個強勢的位置出發。我們今年相對的價格調升幅度可能比一些競爭對手略低。所以我們已經有非常有利的價格位置,然後再從那個基礎上做 14% 的價格調升。因此我們認為,從競爭角度來看,我們的定價——如你所說,這是逐一 MSA 的競賽——但就整體保單組合(book)而言,我們對我們的表現感到滿意。
When you think about the buildup of that 14%, again, it's in rank order starts with trend, which we've built in something that's in the high single digits for trend. Then you've got that impact from market morbidity related to some of the PI initiatives that we've discussed. And then on top of that, we've got a bit of margin enhancement that we also built into price. So those are the building blocks on the pricing.
當你思考這 14% 的構成時,同樣地,按重要性排序,首先是趨勢(trend),我們在趨勢上納入了高個位數的假設。接著是市場疾病率的影響,與我們討論過的一些 PI(特殊投保期)措施相關。然後在此之上,我們也在價格中納入了一點利潤率提升。所以這些就是定價的組成要素。
Operator
Operator
(Operator Instructions)
(接線員指示)
Jonathan Yong, UBS.
Jonathan Yong,瑞銀(UBS)。
Jonathan Yong - Analyst
Jonathan Yong - Analyst
I guess just based on the landscape file, it does look like one of your competitors has gotten a little bit more, I'll call it, aggressive in terms of how they're pricing and coming in as the cheapest option in the market. I guess from your perspective, how do you consider your pricing relative to that? And is it most important to be at the cheapest end of the market? Or how are you viewing that alongside metal tier mix for 2027?
我想就景觀檔(landscape file)來看,確實看起來你們的一位競爭對手在定價上變得更——我姑且稱之為——更具侵略性,並以市場中最便宜的選項進場。我想從你們的角度,你們如何看待相對於對方的定價?而在市場中處於最便宜的一端是否最重要?或者你們如何把這件事與 2027 年的金屬層級組合(metal tier mix)一起看?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
I'll start on price.
我先談價格。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Go ahead, Scott.
你先請,Scott。
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Okay, go ahead, Mark.
好,你先請,Mark。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
I was just going to say that, obviously, metal mix that matters very much, number one. Number two, we believe that it's not just price, it's the quality of the product, quality of customer service. We tend to have higher retention than our competitors do as a result. We have higher NPS scores. So as we look at all of that, it's a mix of capability and our relationship with our customers and our distribution channel that matter. It's not just a price point. Scott?
我只是想說,顯然,金屬層級組合非常重要,這是第一點。第二,我們相信不只是價格,還包括產品品質與客戶服務品質。因此我們的續保率往往比競爭對手更高。我們的 NPS(淨推薦值)分數也更高。所以當我們綜合考量這些因素時,關鍵在於能力、我們與客戶及分銷通路的關係所形成的組合。不只是單一價格點。Scott?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes, I think you hit on it. The point I was going to make, Mark, is that it's really a question of -- you have to be within a relatively reasonable range of the lowest. We feel like we've got really strong price positions in our markets and Mark talked about the distribution and the right products.
是的,我認為你說到重點了。我原本想補充的是:這其實是個——你必須在相對合理的範圍內接近最低價——的問題。我們覺得我們在各個市場的價格位置非常強,而 Mark 也談到了分銷與合適的產品。
And we feel like we've got great relationships with our distribution partners, and we have a product that -- we're a member-centric company. We've got a very good brand when it comes to supporting members, and that's a big part of our selling package. And that -- we think that matters beyond just price.
而且我們與分銷夥伴的關係非常好,我們的產品——我們是一家以會員為中心的公司。在支持會員方面,我們有非常好的品牌形象,這是我們銷售方案中很重要的一部分。而且——我們認為這些因素的重要性不僅僅在於價格。
Jonathan Yong - Analyst
Jonathan Yong - Analyst
Okay. Great. And then just going back to the proposed rules for payment year or for 2028. I guess in relation to the pre-verification open enrollment period that is being proposed, do you see this as kind of a benefit in terms of making sure members get enrolled given the pressure on auto enrollment? And then similarly, does this create pressure on G&A from your perspective where brokers may ask for more in terms of commissions, et cetera? Just curious how you're thinking about that.
好的。很好。接著回到針對付款年度、或針對 2028 年的擬議規則。我想就所提議的「預先驗證」開放投保期而言,鑑於自動投保受到壓力,你是否認為這在確保會員完成投保方面算是一項好處?同樣地,從你們的角度,這是否會對 G&A(一般與行政費用)造成壓力,例如經紀人可能會要求更高的佣金等等?想了解你們如何思考這件事。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
We solve that problem first, Jonathan, by going after -- I always like to say brokers like to maximize revenue per joule of energy expended. And so if we can provide tools to them, which we have through Lucie and our EDE, the opportunity is for them to be able to keep their productivity while being able to go through each of these steps. And so that's part of what we've been doing all along. That's what we did when the enhanced subsidies went away.
我們先解決那個問題,Jonathan,方法是鎖定——我一直喜歡說,經紀人會想把每一焦耳能量所能創造的收入最大化。因此,如果我們能提供工具給他們——我們已透過 Lucie 與我們的 EDE 做到了——機會就在於他們能在完成每一個步驟的同時,仍維持生產力。所以這一直是我們在做的事情之一。這也是在加強補貼取消時我們所做的。
We made it easy for them to move people to new products. And they moved some of our competitors' people to our new products as a result. So I think you have to look at it from the -- again, from the perspective of what do they need to do, how can we help them with tools. And it doesn't necessarily mean that we have to have the highest commissions. As a matter of fact, and Scott, I check with you on this. I believe we are not the highest commission program in the country.
我們讓他們能很容易把人轉移到新產品上。結果他們也把一些競爭對手的客戶轉到我們的新產品上。所以我認為你必須從——再次,從他們需要做什麼、我們如何用工具協助他們的角度來看。而這不一定代表我們必須提供最高的佣金。事實上,Scott,我跟你確認一下。我相信我們並不是全國最高佣金的方案。
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
That's right. I mean our commission strategy generally is to be competitive, but we don't feel like we need to be the highest. I think that the products and the service sells itself.
沒錯。我的意思是,我們的佣金策略一般是保持競爭力,但我們不覺得需要做到最高。我認為產品與服務本身就能自我銷售。
Operator
Operator
Michael Ha, Baird.
Michael Ha,Baird。
Michael Ha - Senior Reseach Analyst
Michael Ha - Senior Reseach Analyst
As you look at '27, I know you're expecting stabilizing metal mix next year. But I wanted to ask your thoughts on like a potential scenario where bronze members could trade up into gold, meaning like could there be an environment where bronze members, maybe they deferred care this past year because of the higher deductibles? Could that have worsened their health or acuity? And so next year, then they shift to gold, lower deductibles, unlock care for members that previously deferred.
當你們看待 2027 年時,我知道你們預期明年的金屬層級組合會趨於穩定。但我想請教你們對一種潛在情境的看法:青銅級會員可能升級到黃金級——也就是說,是否可能出現一種環境,青銅級會員可能因為今年自付額較高而延後就醫?這是否可能讓他們的健康狀況或病情嚴重度變差?因此明年他們轉到黃金級、較低自付額,進而解鎖先前延後的醫療需求。
Like how are you thinking about the possibility of that happening? How much of that migration have you assumed? Like what allowance would you build in your '27 pricing that has some sort of catch-up utilization beyond your normal gold plan assumptions?
你們如何看待這種情況發生的可能性?你們假設了多少這類遷移?在你們 2027 年定價中,你們會納入多少額度,用以反映超出一般黃金計畫假設的「補償性」使用量(catch-up utilization)?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Well, I will start off by saying you are correct. We do expect a similar metal mix. We're not seeing any kind of thematic things that would suggest that there's some delay in utilization, right? It's not like 2026 where we were worried, and then we built in an expectation of higher fourth quarter utilization because people knew they were losing their subsidy. I don't think that's quite what we're seeing.
嗯,我先說你說得沒錯。我們確實預期金屬層級組合會相近。我們沒有看到任何主題性的跡象顯示使用量有延後,對吧?不像 2026 年那樣我們曾擔心,並且因為人們知道要失去補貼,而在模型中納入第四季使用量較高的預期。我不認為我們現在看到的是那種情況。
And on the MOOP side, at maximum out-of-pockets, we are seeing a progression there, which looks to us like behavior that we have seen over a longer period. So again, it doesn't look like people are not using care because they've got a deductible that they have to cover a portion of those costs.
而在 MOOP(最高自付額)方面,我們確實看到其進展,對我們而言看起來像是我們長期以來觀察到的行為模式。所以再次,這看起來不像是人們因為需要先負擔部分成本的自付額而不去使用醫療服務。
So when I kind of pull back and I look at the pricing build that we did for '27, we think we've done the appropriate amount of risk analysis of where in the metals do we see people growing, what does utilization look like? And we're excited about the products we've got out in the market and about our opportunity for the year.
所以當我退一步看我們為 2027 年所做的定價建模,我們認為已就各金屬層級中人們在哪裡成長、使用量長相如何,做了適當程度的風險分析。我們對已投放市場的產品,以及今年的機會感到振奮。
Mark Bertolini - Chief Executive Officer, Director
Mark Bertolini - Chief Executive Officer, Director
Michael, I would add just one thing about Lucie. So Lucie helps people find the right plan in the ACA, not necessarily an Oscar plan, but also connects them to a thing called Allstate Health Solutions that offer coverage for higher deductibles on a premium basis. So people can actually buy protection based on that underlying cover. So they have more than an option of just going up to gold, they could consider a plan like Allstate Health Solutions that helps cover some of those expenses when they occur.
Michael,我再補充一點關於 Lucie。Lucie 會協助人們在 ACA 中找到合適的方案,不一定是 Oscar 的方案,同時也會把他們連結到一個叫 Allstate Health Solutions 的產品,該產品以保費形式提供針對高自付額的保障。因此,人們其實可以基於那個底層保障去購買額外保護。所以他們不只有升級到黃金級這一種選擇,也可以考慮像 Allstate Health Solutions 這樣的方案,在費用發生時協助支付部分支出。
Michael Ha - Senior Reseach Analyst
Michael Ha - Senior Reseach Analyst
Interesting. Helpful. And my next question, just the one key remaining question to me after your ID was really the latest Wakely data that confirms the stabilizing risk pool even after all these CMS lives were removed, identified lives. I just wanted to ask if you could provide a bit more detail on what that Wakely file showed about market morbidity relative to your assumptions.
有意思。很有幫助。我下一個問題——在你們談完 ID 之後,對我而言剩下的一個關鍵問題是:最新的 Wakely 數據確認,即使移除了所有這些 CMS 的人頭(已識別的人頭)之後,風險池仍趨於穩定。我想請你們更詳細說明一下,那份 Wakely 檔案對於市場疾病負擔(morbidity)相對於你們假設顯示了什麼。
And also of all the new integrity measures, all the verification checks, everything new happening next year, curious, which one do you think has the biggest range of uncertainty and how it could impact membership into next year?
另外,面對所有新的誠信措施、所有新的驗證檢核,以及明年將發生的一切新措施,我也好奇:你們認為哪一項的不確定性範圍最大,以及它可能如何影響明年的會員數?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. Well, a lot to unpack there. I would say that with respect to Wakely, latest Wakely white paper shows market morbidity moving as we would have anticipated. And I think that it just reaffirms the estimates that we've been making are appropriate, slightly favorable to our pricing expectations.
是的,這裡面有很多可以拆解。我會說,就 Wakely 而言,最新的 Wakely 白皮書顯示市場疾病負擔的變化符合我們的預期。我認為這也再次確認我們一直以來的估計是適當的,且對我們的定價預期略為有利。
I do think it's important to note that the first Wakely risk report we got in the first quarter was quite favorable. We got that in the second quarter. And then the report that we received in the third quarter is now moderately favorable.
我確實認為需要注意的是,我們在第一季拿到的第一份 Wakely 風險報告相當有利。我們在第二季拿到那份。而我們在第三季收到的這份報告,現在則是中度有利。
We think that is the effect of the CMS program integrity efforts and removing some lives and those are mainly non-utilizers. So we still believe, though, that market morbidity continues to be moderately favorable to where we priced and we're -- we think that gives us a good position for closing out '26.
我們認為這是 CMS 計畫誠信(program integrity)努力的效果,移除了部分人頭,而那些主要是不使用醫療服務的人。不過我們仍相信,市場疾病負擔相對於我們的定價仍是中度有利——我們認為這讓我們在結束 2026 年時處於良好位置。
Operator
Operator
Kevin Fischbeck, Bank of America.
Kevin Fischbeck,美國銀行。
Joaquin Arriagada Martinez - Analyst
Joaquin Arriagada Martinez - Analyst
This is Joaquin Arriagada Martinez on for Kevin. I just wanted to ask about on the 17% to 18% risk adjustment range that you guys gave, is this something that will continue in 2027? Or does that reset back to the 20% range?
我是 Joaquin Arriagada Martinez,代 Kevin 提問。我想問一下,你們給出的 17% 到 18% 風險調整(risk adjustment)區間,這會在 2027 年延續嗎?還是會回到 20% 左右的區間?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. I would say that the 17% to 18% for this year is specific to the risk of the book. And so we'll give you guidance on where we think next year is going to come out. And it really depends on the books and the markets and the metal mix. So I wouldn't want to get ahead of our full year guidance.
是的。我會說,今年的 17% 到 18% 是針對這本業務(book)的風險特性。我們會在提供全年指引時,給你們我們認為明年會落在哪裡的指引。而這真的取決於業務組合與市場,以及金屬層級組合。所以我不想在我們完整的全年指引之前先行透露。
Joaquin Arriagada Martinez - Analyst
Joaquin Arriagada Martinez - Analyst
All right. And could you give us some more color on the trend commentary? What specifically in outpatient is higher? And how are you translating that to your initiatives?
好的。另外你能否就趨勢(trend)的評論提供更多細節?門診(outpatient)具體是哪些項目較高?你們又如何把這些轉化到你們的各項措施上?
Richard Blackley - Chief Financial Officer
Richard Blackley - Chief Financial Officer
Yes. We do see a bit of a trade-off between inpatient and outpatient, which is honestly beneficial for the cost of the member. It's beneficial to us. It's a lower -- typically a lower cost of care. And this is really doing things that are -- some of it is being driven by affordability initiatives that we're executing, which is really kind of just the fundamental blocking and tackling of how you run a health plan.
是的。我們確實看到住院與門診之間有一些此消彼長的情況,坦白說這對會員的成本是有利的。這對我們也有利。因為通常這代表較低的照護成本。而這其實是在做一些——其中一部分是由我們正在執行的可負擔性(affordability)措施所驅動,基本上就是經營健康保險計畫的基本功與日常執行。
It's things like making sure that we're doing clinical reviews that are looking at distinguishing observation from inpatient admissions, things like discharge planning, making sure that, that is done in appropriate time frames. So nothing that I think is out of the ordinary in terms of what we see with the health plan. We're just -- as Mark likes to say, we're constantly trying to progressively eliminate failure.
例如,確保我們進行的臨床審查能區分觀察(observation)與住院收治(inpatient admissions),像是出院規劃(discharge planning),確保這些都在適當的時間範圍內完成。所以就我們在健康保險計畫中看到的情況而言,我不認為有什麼不尋常。我們只是——如 Mark 喜歡說的——我們一直在持續、逐步地消除失敗。
And we're seeing the benefits of that strong operating cadence in both the results on the MLR side, on lower DCPs. So overall, I think that you can see the evidence that we're running a very effective health plan in the numbers.
而我們也在 MLR 端的結果、以及較低的 DCPs 上看到這種強勁營運節奏帶來的效益。因此整體而言,我認為你可以從數字中看到證據:我們正在經營一個非常有效率的健康保險計畫。
Operator
Operator
Ating this time, we have reached our allotted time for questions. We'd like to thank everybody for joining today's conference call. Please feel free to disconnect at any time.
此時,我們已到達提問的預定時間。感謝各位參加今天的電話會議。各位可隨時中斷連線。